Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Seres Therapeutics, Inc. (MCRB)
Price$4.21Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $789,000 | $0 | $0 | $7.1M | $143.9M | $11.9M | $27.2M | $26.9M | $32.1M | $21.8M | $0 | — | — |
| Research & development | $49.1M | $64.6M | $117.6M | $109.7M | $141.9M | $90.6M | $80.1M | $96.0M | $89.5M | $82.0M | $38.1M | $10.7M | $4.8M |
| Operating expenses | $94.8M | $121.3M | $195.1M | $179.9M | $209.4M | $121.3M | $106.4M | $128.6M | $123.5M | $114.6M | $54.9M | $15.1M | $6.1M |
| Operating income | −$94.0M | −$121.3M | −$195.1M | −$179.9M | −$64.5M | −$88.1M | −$71.9M | −$100.3M | −$91.4M | −$92.8M | −$54.9M | −$15.1M | −$6.1M |
| Operating margin | −11,910.14% | — | — | −2,524.05% | −44.83% | −740.77% | −264.37% | −372.57% | −284.72% | −426.53% | — | — | — |
| EBITDA | −$89.8M | −$115.8M | −$188.9M | −$173.3M | −$58.5M | −$81.6M | −$64.3M | −$92.4M | −$84.1M | −$88.6M | −$54.1M | −$14.9M | −$6.0M |
| EBITDA margin | −11,386.31% | — | — | −2,431.05% | −40.70% | −685.48% | −236.40% | −343.36% | −262.11% | −407.21% | — | — | — |
| Net income | $5.7M | $136,000 | −$113.7M | −$250.2M | −$65.6M | −$89.1M | −$70.3M | −$98.9M | −$89.4M | −$91.6M | −$54.8M | −$16.7M | −$6.1M |
| Net profit margin | 721.93% | — | — | −3,509.50% | −45.59% | −749.16% | −258.49% | −367.58% | −278.44% | −420.74% | — | — | — |
| Basic EPSper basic share | $0.64 | $0.00 | -$17.77 | -$2.31 | -$0.72 | -$1.12 | -$1.24 | -$2.43 | -$2.21 | -$2.30 | -$2.33 | -$2.67 | -$1.09 |
| Diluted EPSper diluted share | $0.64 | $0.00 | -$17.77 | -$2.31 | -$0.72 | -$1.12 | -$1.24 | -$2.43 | -$2.21 | -$2.30 | -$2.33 | -$2.67 | -$1.09 |
Owners
Reported shareholders
11.76%of listed shares
Flagship Pioneering, LLC1.16M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
NESTLE SA / Societe des Produits Nestle S.A. | —21.88M shares |
Flagship Pioneering, LLC | 11.76%1.16M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.93%287.78K shares |
MARSHALL WACE, LLP | 1.75%172.25K shares |
Vontobel Holding Ltd. | 1.25%122.98K shares |
BlackRock, Inc. | 1.13%111K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.81%79.97K shares |
Ege David S. | ≈0.79%77.58K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.59%58.33K shares |
VANGUARD FIDUCIARY TRUST CO | 0.50%48.69K shares |
von Moltke Lisa | ≈0.41%39.88K shares |
STATE STREET CORP | 0.34%33.9K shares |
Lion Point Capital, LP | 0.32%31.57K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.32%31.05K shares |
AMERICAN CENTURY COMPANIES INC | 0.29%28.31K shares |
XTX Topco Ltd | 0.21%20.73K shares |
GOLDMAN SACHS GROUP INC | 0.15%15.23K shares |
NORTHERN TRUST CORP | 0.15%14.77K shares |
Invesco Ltd. | 0.13%12.97K shares |
MORGAN STANLEY | 0.12%12.14K shares |
Percentages use 9.83M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 · 10b5-1 | Shaff Eric D.Director | SellCommon Stock | 259 | $7.53 | $2.0K | 12.0K |
| May 18, 2026Form 4 | Brady KellySee Remarks | SellCommon Stock | 59 | $7.53 | $444.27 | 8.6K |
| May 18, 2026Form 4 · 10b5-1 | DesRosier ThomasSee Remarks | SellCommon Stock | 79 | $7.53 | $594.87 | 8.0K |
| May 18, 2026Form 4 · 10b5-1 | Henn Matthew RSee Remarks | SellCommon Stock | 77 | $7.53 | $579.81 | 7.8K |
| Feb 15, 2026Form 4 · 10b5-1 | Young Teresa L.See Remarks | SellCommon Stock | 75 | $8.47 | $635.25 | 8.6K |